Policy, Biotech Chris Morrison Policy, Biotech Chris Morrison

Innovation and biopharma M&A: feature, not bug

If the FTC begins to look askance at M&A between commercial-stage biopharmaceutical companies and the innovative smaller biotechs that so often are the sources of new medicines, that would be bad news for future R&D and the patients who depend on our industry for life-saving medicines. That they might do so in the name of preserving or protecting innovation in the first place would add insult to injury.

Read More